How does Lecanemab work?

Lecanemab, also known as the brand name Leqembi, is an anti-amyloid monoclonal antibody approved by the FDA in January 2023 for the treatment of early stages of Alzheimer’s disease. There are two proteins that accumulate in the brains of people with Alzheimer’s disease: beta-amyloid and tau. Both are toxic to the brain and cause neuronal loss. Lecanemab binds selectively to aggregated forms of beta-amyloid to help the immune system remove it from the body.
To learn more about Alzheimer’s disease treatment and care at UCLA, please speak with your primary care doctor or call the UCLA Neurology Outpatient Clinic: 310-794-1195.
You can also visit our website to find a provider, schedule an appointment, and learn more about treatment and care options: www.uclahealth...